ACAD Research | Milton Maxwell

ACAD

ACADIA Pharmaceuticals Inc.

26.80

-0.46-1.69%

Dec 16, 4:00:02 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

FY Q4 '25

Reaffirms growth, details pipeline risks.

2/25/26Feb 25, 2026

Q&A largely reaffirmed prepared guidance on NUPLAZID's low-teens and DAYBUE's low-20s growth to 2028 targets, bridging 2026 midpoints with steady execution. Management detailed remlifanserin Phase II powering for 0.4 SAPS-HD effect size, pimavanserin-inspired exposure response, and dosing edge over Cobenfy in frail patients. Early STIX buzz eyes 400+ incremental Rett patients over 2-3 years; field expansions already boosting NUPLAZID referrals. EU reexam precedent hints 20-30% reversal shot despite endpoint concerns. No trial irregularities flagged. Remplifanserin readout matters most now.

Key Stats

Market Cap

4.53B

P/E (TTM)

17.29

Basic EPS (TTM)

1.55

Dividend Yield

Recent Filings

8-K

New board appointment

3/5/26Mar 5, 2026

Acadia Pharmaceuticals appointed Jonathan M. Poole to its board and Audit Committee on March 3, 2026, filling a vacancy as a Class II director through the 2027 annual meeting. He receives $50,000 annual board retainer plus $12,500 for Audit duties, an initial $200,000 equity grant vesting over three years, and a prorated $95,300 grant. Future annual equity: $400,000. No family ties or side deals.

10-K

FY2025 results

2/26/26Feb 26, 2026

Acadia Pharmaceuticals drove FY2025 net product sales to $1,071.5 million, up 11.9% y/y from $957.8 million in FY2024, with NUPLAZID contributing $680.1 million (up 11.6% y/y) and DAYBUE $391.4 million (up 12.4% y/y); Q4 momentum accelerated as both franchises gained share amid field force expansion and direct-to-consumer campaigns. Quarterly trends showed accelerating growth rates and margin stability, fueled by NUPLAZID's 25% market share in PDP and DAYBUE's new patient adoption in Rett syndrome. Cash reserves swelled to $819.7 million, supporting R&D on remlifanserin Phase 2 trials in ADP/LBDP. EU approval risks for DAYBUE loom from CHMP's negative trend vote.

8-K

Acadia hits $1B+ revenue

2/25/26Feb 25, 2026

Acadia topped $1.07B in 2025 GAAP revenues, up 12% YoY, with NUPLAZID at $680M and DAYBUE at $391M despite a $20M IRA rebate hit. Non-GAAP adjusted revenues hit $1.08B. Guidance calls for $1.22-1.28B in 2026. Cash swelled to $820M.

8-K

2025 sales top $1B

1/13/26Jan 13, 2026

Acadia Pharmaceuticals reaffirmed at the J.P. Morgan Healthcare Conference on January 13, 2026, that 2025 net sales will exceed $1 billion, matching prior guidance. The company posted slides on ir.acadia.com. Guidance holds firm.

10-Q

Q3 FY2025 results

11/6/25Nov 6, 2025

Acadia's Q3 revenue jumped 11% y/y to $278.6M from $250.4M, with NUPLAZID up 12% to $177.5M and DAYBUE up 11% to $101.1M, driving operating income to $35.8M (up 13% y/y) at ~13% margins while R&D rose on ACP-204 and ACP-101. Diluted EPS hit $0.42, more than doubling y/y on 170.7M shares, boosted by a $27.2M tax benefit from OBBBA. Operating cash flow for 9M totaled $158.6M; cash and investments stood at $847M with no debt. Intangible assets of $111.6M reflect DAYBUE licensing amortized through 2036. Patent suits shield NUPLAZID from generics. Litigation clouds persist.

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

CEO

Ms. Catherine E. Owen Adams

IPO

5/27/2004

Website

https://www.acadia.com

Employees

653

Sector

Healthcare

Industry

Biotechnology